And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...
Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...
MADISON, Wis., December 03, 2024--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific ...
Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined service can identify ...
Bicara Therapeutics Inc. (BCAX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns.Don't Miss our Black Friday ...
At close: December 2 at 4:00 PM EST ...
Primary antiphospholipid syndrome (PAPS) is a clotting disorder attributed to autoreactive antibodies produced by B cells. Here the authors show, using single cell omics and B cell repertoire data ...
Aa Aaaa Aa 123.64 +34.98% ...